Status:

RECRUITING

The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.

Lead Sponsor:

Ali Asmar

Collaborating Sponsors:

University of Copenhagen

The Augustinus Foundation, Denmark.

Conditions:

Kidney Diseases

Eligibility:

MALE

20-60 years

Phase:

NA

Brief Summary

The goal of this crossover study is to investigate to what extend glucagon affects the kidneys. The main questions it aims to answer are: Does glucagon regulate kidney function through extraction in ...

Detailed Description

In patients with type 2 diabetes mellitus, plasma concentrations of glucagon are inappropriately high (hyperglucagonemia). Hyperglucagonemia has been speculated to contribute to the pathophysiology of...

Eligibility Criteria

Inclusion

  • Age: 20-60 years
  • Normal health ascertained through questioning and medical examination
  • Normal values for blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function, and electrolytes
  • Informed consent

Exclusion

  • Immunosuppressive treatment in the preceding 12 months
  • Alcohol abuse
  • Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the investigator, may interfere with glucose metabolism
  • Use of lithium
  • Medical treatment that affects insulin secretion or cardiovascular performance measures
  • Liver disease (ALT \> 2x normal value)
  • Renal impairment (se-creatinine \> 130 μM and/or albuminuria)

Key Trial Info

Start Date :

February 20 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2025

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT06498063

Start Date

February 20 2024

End Date

July 31 2025

Last Update

July 12 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Physiological laboratory, Bispebjerg Hospital, Research Unit, Clinical Physiology / Nuclear Medicine Department

Copenhagen, Denmark, 2400